<DOC>
	<DOCNO>NCT02829372</DOCNO>
	<brief_summary>The purpose study determine safety profile maximum tolerable dose ( MTD ) GBR 1302 monotherapy subject HER2 positive cancer</brief_summary>
	<brief_title>Phase 1 Study Single Agent GBR 1302 Subjects With HER2 Positive Cancers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>1 . Progressive HER2 positive solid tumour ( immunohistochemistry [ IHC ] positive equivocal ) available standard curative treatment . 2 . Eastern Cooperative Oncology Group ( ECOG ) performance score 02 . 3 . Subjects enter Cohort 1 2 need preexisting , functioning , central venous access place administration study drug . 1 . Active infectious disease consider Investigator incompatible protocol . 2 . Patients recover therapyrelated toxicity previous therapy least CTCAE â‰¤ Grade 1 except case liver metastases Gilbert 's Syndrome alopecia . 3 . Brain metastasis symptomatic untreated require current therapy . 4 . Previous treatment immunotherapy within 8 week start study medication , chemotherapy , radiotherapy , moleculartargeted therapy , biological therapy ( include HER2 direct therapy ) within 4 week start study medication , hormone therapy within 2 week start study medication . 5 . Use investigational drug within past 4 week start study medication concomitantly study except investigational immunestimulatory therapy ( e.g . checkpointregulator target treatment ) . The minimum washout period 8 week start study medication . 6 . Any history evidence clinically significant cardiovascular disease define least one follow criterion : 1 . Baseline Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % major wall dyskinesia via echocardiography ( ECHO ) . 2 . History evidence poorly control arterial hypertension ( systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 100 mmHg ) . 3 . Cardiac arrhythmia require antiarrhythmic therapy , except betablockers , calcium antagonist digoxin . 4 . Clinically significant valvular heart disease . 5 . Myocardial infarction instable angina pectoris within previous 6 month . 6 . Documented history congestive heart failure ( CHF ) New York Heart Association ( NYHA ) criterion . 7 . History exposure cumulative dos anthracyclines follow : prior anthracycline cumulative exposure &gt; 360 mg/m2 doxorubicin equivalent . 7 . Known allergy ingredient formulation know allergy related class compound .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>